

Center for HIV, STD, and TB Prevention, CDC, Corporate Square Office Park, 11 Corporate Square Boulevard, M/S E07, Atlanta, Georgia 30329, telephone 404/639-8025, e-mail EOW1@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: October 4, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99-26482 Filed 10-8-99; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Meeting

Office of the Director, Centers for Disease Control and Prevention (CDC), announces the following meeting.

Name: Guide to Community Preventive Services (GCPS) Task Force Meeting;

Times and Dates: 9 a.m.-3:30 p.m., October 13, 1999; 8:30 a.m.-3:15 p.m., October 14, 1999.

Place: The Sheraton Hotel Atlanta, Courtland and International Boulevard, Atlanta, Georgia 30303, telephone (404) 659-6500.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 40 people.

Purpose: The mission of the Task Force is to develop and publish a Guide to Community Preventive Services, which is based on the best available scientific evidence and current expertise regarding essential public health services and what works in the delivery of those services.

Matters to be Discussed: Agenda items include: an overview and update on the organizational changes and structure of the Guide Activity; update on the current dissemination activities and discussion on future initiatives for the Guide; coordination activities with the Clinical Guide; discussion and review of the current Methods issues; and review and discussion of Chapter development progress for the Tobacco Prevention and Control, Cancer, Prevention of Mental Health Disorders and Motor Vehicle Occupant Injury Chapters.

Agenda items are subject to change as priorities dictate.

FOR FURTHER INFORMATION CONTACT: Stephanie Zaza, M.D., M.P.H., Chief, CPS Guide Development Activity, Division of Prevention Research and Analytic Methods, Epidemiology Program Office, CDC, 4770 Buford Highway, M/S K-73, Atlanta, Georgia 30341, telephone 770/488-8189.

Persons interested in reserving a space for this meeting should call 770/488-8189 by close of business on October 8, 1999.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: October 4, 1999.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 99-26483 Filed 10-8-99; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 98D-0566]

International Cooperation on Harmonisation of Technical Requirements for Approval of Veterinary Medicinal Products (VICH); Final Guidances entitled "Stability Testing of New Veterinary Drug Substances and Medicinal Products" (VICH GL3); "Stability Testing of New Veterinary Dosage Forms" (VICH GL4); "Stability Testing: Photostability Testing of New Veterinary Drug Substances and Medicinal Products" (VICH GL5); Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of three final guidances for industry entitled "Stability Testing of New Veterinary Drug Substances and Medicinal Products" (VICH GL3), "Stability Testing of New Veterinary Dosage Forms" (VICH GL4), and "Stability Testing: Photostability Testing of New Veterinary Drug Substances and Medicinal Products" (VICH GL5). These guidances have been adapted for veterinary use by the International Cooperation on Harmonisation of Technical Requirements for Approval of Veterinary Medicinal Products (VICH) from guidances regarding pharmaceuticals for human use, which were adopted by the International Conference on Harmonisation of Technical Requirements for Approval of Pharmaceuticals for Human Use (ICH). These VICH documents provide

guidance on stability testing of new animal drugs and new dosage forms of new animal drugs included as part of new animal drug applications (referred to as registration applications in the guidances) submitted to the European Union, Japan, and the United States.

DATES: You may submit written comments at anytime.

ADDRESSES: Copies of the final guidance documents entitled "Stability Testing of New Veterinary Drug Substances and Medicinal Products" (VICH GL3), "Stability Testing of New Veterinary Dosage Forms" (VICH GL4), and "Stability Testing: Photostability Testing of New Veterinary Drug Substances and Medicinal Products" (VICH GL5) may be obtained on the Internet from the CVM home page at <http://www.fda.gov/cvm/fda/mappgs/vich.html>. Persons without Internet access may submit written requests for single copies of the final guidance to the Communications Staff (HFV-12), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855. Send one self-addressed adhesive label to assist that office in processing your requests.

You may submit written comments any time on the final guidance documents to the Policy and Regulations Team (HFV-6), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855.

FOR FURTHER INFORMATION CONTACT:

Regarding VICH: Sharon Thompson, Center for Veterinary Medicine (HFV-3), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1798, E-mail, "sthompso@cvm.fda.gov", or

Robert C. Livingston, Center for Veterinary Medicine (HFV-1), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-5903, E-mail, "rlivings@cvm.fda.gov".

Regarding the guidance documents: William G. Marnane, Center for Veterinary Medicine (HFV-140), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-827-6966. E-mail, "wmarnane@cvm.fda.gov".

SUPPLEMENTARY INFORMATION:

I. Background

In recent years, many important initiatives have been undertaken by regulatory authorities, industry associations, and individual sponsors to promote the international